FDA, EMA Seek Biosimilar Pathway Convergence
This article was originally published in The Pink Sheet Daily
Executive Summary
The deputy director of FDA's Europe Office discusses the collaboration between FDA and the European Medicines Agency; the agencies are looking for ways to develop a common biosimilar development program.
You may also be interested in...
Biosimilars: FDA, EMA Developing Common Data Package Guidance
Guidance is “emerging” that will allow sponsors to use data from products not licensed in their respective regions in applications.
Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally
Sandoz has begun a global Phase III trial with its biosimilar version of Amgen's Enbrel (etanercept), targeting psoriasis rather than the more lucrative indication for rheumatoid arthritis, with the aim of winning quicker regulatory approval which can be built on as it gains insights testing the medicine.
Sandoz Biosimilar Strategy For Etanercept: Start Small, But Test Globally
Sandoz has begun a global Phase III trial with its biosimilar version of Amgen's Enbrel (etanercept), targeting psoriasis rather than the more lucrative indication for rheumatoid arthritis, with the aim of winning quicker regulatory approval which can be built on as it gains insights testing the medicine.